The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 206-215

  Ballester, I ^a   Daddaoua, A ^a   Lopez Posadas R ^a   Nieto, A ^b   Suarez M D ^a   Zarzuelo, A ^a   Martinez Augustin O ^a   De Medina, F Sánchez ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Alendronate; Bisphosphonates; Experimental colitis; Inflammatory bowel disease; Interleukin 1; Trinitrobenzenesulfonic acid

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; FEMALE; HEALTH STATUS; IN VIVO STUDY; INTESTINE NECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ALENDRONATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; CHEMOKINE CCL2; COLITIS; COLON; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; RATS; RATS, WISTAR; SULFASALAZINE; TREATMENT OUTCOME; TRINITROBENZENESULFONIC ACID;

EID: 34248588370     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707227     Document Type: Article

References (44)

1. Abeles AM, Pillinger MH (2006). Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 54: 393-407.
2. Banks C, Bateman A, Payne R, Johnson P, Sheron N (2003). Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35.
3. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP (2003). A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 18: 1121-1127.
4. Bernstein CN, Leslie WD (2005). Therapy insight: Osteoporosis in inflammatory bowel disease - advances and retreats. Nat Clin Pract Gastroenterol Hepatol 2: 232-239.
5. Castells A, Paya A, Alenda C, Rodriguez-Moranta F, Agrelo R, Andreu M et al. (2006). Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res 12: 1686-1692.
6. Coxon FP, Thompson K, Rogers MJ (2006). Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6: 307-312.
7. Daddaoua A, Puerta V, Zarzuelo A, Suarez MD, Sanchez de Medina F, Martinez-Augustin O (2005). Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. J Nutr 135: 1164-1170.
8. Gonyeau MJ (2005). Statins and osteoporosis: a clinical review. Pharmacotherapy 25: 228-243.
9. Green JR (2004). Bisphosphonates: preclinical review. The Oncologist 9 (Suppl 4): 3-13.
10. Haderslev KV, Tjellesen L, Sorensen HA, Staun M (2000). Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119: 639-646.
11. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL et al. (1990). Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336-340.
12. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK et al. (1992). Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33: 922-928.
13. Koida M, Fukuyama R, Nakamuta H (2004). Osteoporosis requires bone-specific statins. Curr Pharm Des 10: 2605-2613.
14. Krawisz JE, Sharon P, Stenson WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
15. Licata AA (2005). Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39: 668-677.
16. Lin CL, Moniz C, Chow JW (2000). Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat. Calcif Tissue Int 67: 373-377.
17. Lin JH, Chen IW, Deluna FA (1994). On the absorption of alendronate in rats. J Pharm Sci 83: 1741-1746.
18. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA et al. (2004). Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 138: 323-329.
19. Mathoo JM, Cranney A, Papaioannou A, Adachi JD (2004). Rational use of oral bisphosphonates for the treatment of osteoporosis. Curr Osteoporos Rep 2: 17-23.
20. Monteleone G, Fina D, Caruso R, Pallone F (2006). New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 22: 361-364.
21. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96: 795-803.
22. Neurath M, Fuss I, Strober W (2000). TNBS-colitis. Int Rev Immunol 19: 51-62.
23. Nikolaus S, Folscn U, Schreiber S (2000). Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 47: 71-82.
24. Porras AG, Holland SD, Gertz BJ (1999). Pharmacokinetics of alendronate. Clin Pharmacokinet 36: 315-328.
25. Poulsen SS, Kissow H, Hare K, Hartmann B, Thim L (2005). Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept 126: 163-171.
26. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K (1992). 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 36 (Suppl 1): C37-C46.
27. Reszka AA, Rodan GA (2003). Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1: 45-52.
28. Rogers MJ (2004). From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 75: 451-461.
29. Sanchez de Medina F, Galvez J, Romero JA, Zarzuelo A (1996). Effect of quercitrin on acute and chronic experimental colitis in the rat. J Pharmacol Exp Ther 278: 771-779.
30. Sanchez de Medina F, Martinez-Augustin O, Gonzalez R, Ballester I, Nieto A, Galvez J et al. (2004). Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 68: 2317-2326.
31. Sands BE (2000). Therapy of inflammatory bowel disease. Gastroenterology 118: S68-S82.
32. Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A et al. (2003). The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextransulfate induced colitis. J Pharmacol Exp Ther 305: 78-85.
33. Shovman O, Levy Y, Gilburd B, Shoenfeld Y (2002). Antiinflammatory and immunomodulatory properties of statins. Immunol Res 25: 271-285.
34. Siminovitch KA (2006). Advances in the molecular dissection of inflammatory bowel disease. Semin Immunol 18: 244-253.
35. Stancu C, Sima A (2001). Statins: mechanism of action and effects. J Cell Mol Med 5: 378-387.
36. Stokkers PC, Van Aken BE, Basoski N, Reitma PH, Tytgat GN, Van Deventer SJ (1998). Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 43: 33-39.
37. Stucchi AF, Shofer S, Leeman S, Materne O, Beer E, McClung J et al. (2000). NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 279: G1298-G1306.
38. Van Assche G, Vermeire S, Rutgeerts P (2005). Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21: 443-447.
39. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E et al. (2004). Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127: 502-513.
40. Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR (1990a). Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 98: 269-277.
41. Vilaseca J, Salas A, Guarner F, Rodriguez R, Martinez M, Malagelada JR (1990b). Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 31: 539-544.
42. Von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R et al. (2003). Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 17: 807-816.
43. Woodruff TM, Arumugam TV, Shiels IA, Newman ML, Ross PA, Reid RC et al. (2005). A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol 5: 883-892.
44. Yaturu S (2003). Skeletal effects of statins. Endocr Pract 9: 315-320.